Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Universe Pharmaceuticals's Shareholder Yield % was -904.87%.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Universe Pharmaceuticals Shareholder Yield % Related Terms
Universe Pharmaceuticals Shareholder Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UPC vs CBIH, PRFX, IMCC: Shareholder Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Universe Pharmaceuticals's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Universe Pharmaceuticals Shareholder Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Universe Pharmaceuticals's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Universe Pharmaceuticals's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Universe Pharmaceuticals (UPC) has a Shareholder Yield % of -904.87% as of Sep. 2025. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Universe Pharmaceuticals and its competitors. According to the industry distribution chart, Universe Pharmaceuticals ranks #971 out of 972 companies in the Drug Manufacturers industry, placing it in the top 99.9%.
Is Universe Pharmaceuticals' Shareholder Yield % too high?
Universe Pharmaceuticals' current Shareholder Yield % is -904.87%. Based on the distribution chart, Universe Pharmaceuticals ranks #971 out of 972 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Universe Pharmaceuticals has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Universe Pharmaceuticals' Shareholder Yield % compare to CBIH and PRFX?
According to the Drug Manufacturers industry distribution chart, Universe Pharmaceuticals ranks #971 out of 972 companies for Shareholder Yield %. This places Universe Pharmaceuticals in the lower half of its industry. The industry median Shareholder Yield % is 0.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Drug Manufacturers company?
The median Shareholder Yield % among Drug Manufacturers companies is 0.30, based on 972 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Universe Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Shareholder Yield % is 0.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Universe Pharmaceuticals's current Shareholder Yield % is -904.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Universe Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Universe Pharmaceuticals (UPC) is currently considered Possible Value Trap. The stock's GF Value™ is $5.22, compared to a current price of $2.96 — trading 43.3% below its estimated fair value. The current Shareholder Yield % is -904.87%. Universe Pharmaceuticals' overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Universe Pharmaceuticals (UPC), the current Shareholder Yield % is -904.87% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Universe Pharmaceuticals (UPC) Overvalued in 2026?
Based on GuruFocus' analysis, Universe Pharmaceuticals stock appears to be undervalued.
The current stock price of $2.96 is trading 43.3% below its estimated GF Value™ of $5.22.
GuruFocus considers Universe Pharmaceuticals to be Possible Value Trap.
Key valuation signals for UPC:
Shareholder Yield %: -904.87%
GF Value™: $5.22 vs. price of $2.96 (43.3% below fair value)
No single metric tells the full story. See the UPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.
58GF Score
Get the complete analysis for UPC
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UPC has been successfully added to your 
